The FDA wants to make drug development more efficient and effective by modernizing how the agency collects and evaluates clinical information, allowing adaptive clinical trial designs and master protocols, and communicating more with clinical trial sponsors, investigators, review boards and other stakeholders, Commissioner Scott Gottlieb said.​

Endpoints News
Regulatory Focus
Bloomberg